Metastatic malignant melanoma represents the most challenging stage of skin cancer, when melanoma cells have spread beyond the original site to other parts of the body. While this advanced stage presents serious medical concerns, recent years have brought remarkable progress in treatment options, offering new hope and significantly improved outcomes for many patients through innovative therapies that were unimaginable just a decade ago.

Understanding Treatment Goals and Modern Approaches

When melanoma has spread to distant parts of the body, the focus of treatment shifts toward controlling the disease, managing symptoms, and improving quality of life. The approach to treating metastatic melanoma depends heavily on several factors, including where the cancer has spread, the overall health of the patient, and specific characteristics of the tumor itself. These characteristics can be identified through detailed testing and help doctors choose the most appropriate treatment strategy.^[1]

The landscape of melanoma treatment has transformed dramatically over the past decade. What was once considered a highly resistant cancer with very limited options has become a disease where many patients can live longer, better lives thanks to breakthroughs in understanding how melanoma grows and spreads. Today’s treatment plans often combine different approaches, and doctors work closely with patients to tailor therapy to their individual situation.^[7]

The sites where melanoma spreads can influence both treatment decisions and outcomes. Melanoma most commonly travels to the skin and tissues just beneath it, followed by the lungs, liver, bones, and brain. Each of these locations may require specific considerations when planning treatment. Some patients may have cancer in just one or a few spots, while others may have more widespread disease, and these differences matter when choosing therapy.^[1]

Prognosis, which refers to the likely outcome of the disease, depends on multiple factors beyond just where the cancer has spread. Blood test results, particularly a substance called lactate dehydrogenase (LDH), can provide important information. Elevated LDH levels often indicate more aggressive disease. Additionally, factors such as how well a patient can carry out daily activities, weight loss, and other symptoms all contribute to understanding each person’s unique situation.^[7]

Standard Treatment Approaches

For many years, dacarbazine has been the standard chemotherapy drug approved for treating metastatic melanoma. This medication was first approved by the US Food and Drug Administration in 1975 and works by damaging the DNA of cancer cells, preventing them from growing and dividing. However, response rates to dacarbazine alone are modest, typically ranging from 5% to 20%, and most responses are not long-lasting. Despite these limitations, it remains an option, particularly when other treatments are not suitable.^[7]

Combination chemotherapy, which uses multiple drugs together, has been explored to try to improve upon single-agent results. While these combinations sometimes produce higher response rates, meaning more patients see their tumors shrink temporarily, studies have not shown that they help patients live longer overall. Additionally, combination treatments tend to cause more side effects than single drugs, which can affect quality of life during treatment.^[7]

One important immunotherapy option that has been available for over two decades is high-dose interleukin-2 (IL-2), which was approved in 1998. Interleukin-2 is a naturally occurring protein that helps stimulate the immune system to fight cancer. When given in high doses, it can produce remarkable results in a small percentage of patients, with some achieving complete remission that lasts for many years. The challenge is that high-dose IL-2 requires hospitalization, causes significant side effects including flu-like symptoms, low blood pressure, and fluid retention, and only benefits about 6-10% of patients. Identifying which patients are most likely to benefit remains difficult.^[7]

Surgery still plays a role in selected cases of metastatic melanoma, though it is not the primary treatment for most patients. When melanoma has spread to only one or a few small areas in the skin, a single group of lymph nodes, or isolated spots in organs like the lung, liver, brain, or small intestine, surgical removal may be considered. This approach can relieve symptoms and may improve outcomes when combined with other treatments. For patients with brain metastases causing symptoms, surgery or specialized radiation techniques like gamma knife can provide relief and control the disease in that location.^[8][11]

Radiation therapy serves an important palliative role, meaning it helps control symptoms and improve comfort even when it cannot cure the disease. Radiation can effectively treat painful bone metastases, reduce the size of tumors pressing on nerves or other structures, and manage brain metastases. The treatment involves using high-energy rays to damage cancer cells in the targeted area, with minimal impact on surrounding normal tissue.^[8]

Revolutionary Immunotherapy Treatments

The most significant breakthrough in melanoma treatment has been the development of immune checkpoint inhibitors. These drugs work by releasing the natural brakes on the immune system, allowing it to recognize and attack melanoma cells more effectively. Our immune system normally has built-in checkpoints that prevent it from attacking our own tissues, but cancer cells cleverly exploit these checkpoints to hide from immune surveillance. Checkpoint inhibitors block these protective mechanisms, unleashing the immune system against the cancer.^[8][12]

Nivolumab and pembrolizumab are drugs that block a checkpoint protein called PD-1 (programmed death-1). When PD-1 is blocked, T cells, which are the immune system’s soldiers, can better attack melanoma cells. These medications are given through an intravenous infusion, typically every two to six weeks depending on the specific drug and dosing schedule. Many patients experience tumor shrinkage, and importantly, some responses last for years, suggesting possible long-term disease control.^[8]

Another approach involves blocking a checkpoint called CTLA-4 using a drug called ipilimumab. This medication works earlier in the immune response process than PD-1 inhibitors, activating T cells in different ways. While effective, ipilimumab used alone tends to cause more immune-related side effects than PD-1 inhibitors.^[8]

One of the most promising strategies combines ipilimumab with nivolumab. This combination attacks the cancer through two different immune pathways simultaneously, leading to higher response rates than either drug alone. However, this dual approach also increases the likelihood and severity of side effects, so it requires careful patient selection and close monitoring. Studies have shown that many patients who respond to this combination maintain their response for extended periods.^[8][11]

A newer combination approved for treatment is nivolumab plus relatlimab, marketed as Opdualag. Relatlimab blocks a different checkpoint called LAG-3, providing yet another way to activate the immune system. This combination offers an alternative for patients, with studies showing effectiveness and a different side effect profile compared to the ipilimumab-nivolumab combination.^[8]

Side effects from checkpoint inhibitors differ from traditional chemotherapy. Instead of causing hair loss, nausea, and low blood counts, these drugs can cause immune-related adverse events. Because they activate the immune system broadly, the immune response can sometimes target normal tissues, leading to inflammation in various organs. Common immune-related side effects include rash, diarrhea and colitis (inflammation of the colon), hepatitis (liver inflammation), and thyroid problems. More rarely, these drugs can affect the lungs, nervous system, or other organs. Most immune side effects can be managed with medications that suppress the immune system, such as steroids, but they require prompt recognition and treatment.^[12]

An innovative type of immunotherapy called lifileucel (Amtagvi) uses tumor-infiltrating lymphocytes (TILs). This highly personalized approach involves removing a patient’s tumor, isolating immune cells that have naturally infiltrated it, growing these cells to large numbers in the laboratory, and then infusing them back into the patient. This therapy has shown promise for patients whose melanoma has progressed after other treatments.^[8]

For patients with cancer limited to nearby skin areas or in-transit metastases (cancer that has spread through lymph vessels but not to distant organs), localized immunotherapy can be used. Aldesleukin (interleukin-2) can be injected directly into tumors, providing a concentrated immune response at the cancer site without the severe side effects of high-dose systemic IL-2. This can be combined with imiquimod, an immune-activating cream applied directly to the skin. Another topical option is diphenylcyclopropenone (DPCP), which causes a controlled allergic reaction that can help the immune system recognize and attack melanoma cells in the treated area.^[8]

Targeted Therapy Based on Tumor Genetics

Understanding the genetic makeup of melanoma has led to the development of targeted therapies that specifically attack cancer cells with particular mutations while largely sparing normal cells. The most important genetic change in melanoma is the BRAF V600 mutation, present in approximately 40-50% of melanomas. The BRAF protein normally helps control cell growth, but when mutated, it becomes constantly active, driving uncontrolled cell division and tumor growth.^[8]

BRAF inhibitors are drugs designed to block the activity of mutated BRAF protein. Three BRAF inhibitors are approved for melanoma: dabrafenib, vemurafenib, and encorafenib. These medications are taken orally as pills every day. When used alone, they can produce dramatic tumor shrinkage in many patients, often within weeks. However, the cancer typically develops resistance over time, with most tumors beginning to grow again after several months.^[8]

To overcome resistance and improve outcomes, BRAF inhibitors are now always combined with MEK inhibitors. MEK is a protein that works downstream of BRAF in the same growth-signaling pathway. Blocking both BRAF and MEK together produces more complete pathway blockade, delays resistance, and improves survival compared to BRAF inhibitors alone. The approved combinations are dabrafenib with trametinib, vemurafenib with cobimetinib, and encorafenib with binimetinib. All combinations are taken as oral medications daily.^[8][11]

Response rates to BRAF/MEK inhibitor combinations are high, often 60-70% or more, with many patients experiencing rapid tumor shrinkage. This quick response can be particularly valuable for patients with symptoms from their cancer or rapidly growing disease. The treatment continues as long as it remains effective and tolerable, with some patients maintaining responses for several years, though most eventually develop resistance.^[8]

Side effects of targeted therapy differ from both chemotherapy and immunotherapy. Common issues include fever, fatigue, nausea, diarrhea, and skin changes such as rash, dry skin, and increased sun sensitivity. BRAF inhibitors can paradoxically cause new skin cancers called squamous cell carcinomas in a small percentage of patients; regular skin monitoring is essential during treatment. Joint pain and swelling can occur, and some patients experience vision changes or heart problems that require monitoring. Most side effects are manageable with dose adjustments or supportive medications.^[8]

For melanomas with different genetic changes, other targeted therapies exist. Patients whose tumors have a C-KIT mutation, which is more common in certain melanoma subtypes like those arising on palms, soles, or mucous membranes, may benefit from imatinib. This drug, originally developed for chronic myeloid leukemia, can block the abnormal KIT protein. However, c-KIT mutations are relatively rare in melanoma, occurring in only a small percentage of cases.^[8]

Ongoing Research and Clinical Trials

Clinical trials represent the frontier of melanoma treatment, where new drugs and approaches are tested before becoming standard options. Participating in a clinical trial can provide access to cutting-edge therapies and contributes to advancing knowledge that helps future patients. Given the rapid pace of melanoma research, patients and doctors are strongly encouraged to consider clinical trials, particularly when disease progresses after initial treatment.^[6]

Researchers are actively investigating numerous questions to further improve outcomes. One major focus is understanding why some patients respond to immunotherapy while others do not, and identifying ways to increase the percentage of patients who benefit. Studies are exploring whether combining immunotherapy with other treatments, such as targeted therapy, radiation, or other types of immune-stimulating drugs, can improve results.^[12]

The timing and sequencing of treatments is another important research question. For patients with BRAF-mutant melanoma who are candidates for both targeted therapy and immunotherapy, determining which approach to use first remains under investigation. Some trials are studying whether starting with targeted therapy to quickly shrink tumors, then switching to immunotherapy for longer-lasting control, provides better outcomes than starting with immunotherapy alone. Other studies examine whether combining both approaches from the beginning offers advantages despite increased toxicity.^[11]

Novel immunotherapy approaches are in various phases of clinical testing. These include drugs targeting additional immune checkpoints beyond PD-1, CTLA-4, and LAG-3, as well as therapies designed to activate the immune system through different mechanisms. Cancer vaccines, which train the immune system to recognize specific melanoma proteins, are being studied both alone and in combination with checkpoint inhibitors. Some vaccines use messenger RNA technology similar to COVID-19 vaccines, delivering instructions for melanoma proteins to immune cells.^[12]

Cellular therapies beyond TIL therapy are under investigation. Some approaches involve engineering a patient’s own T cells in the laboratory to express special receptors that recognize melanoma cells, then infusing these modified cells back into the patient. These engineered T cells can potentially seek out and destroy cancer cells throughout the body. Early phase trials are evaluating the safety and effectiveness of various cellular therapy strategies.^[11]

Researchers are also studying the role of the microbiome—the trillions of bacteria and other microorganisms living in our intestines—in melanoma treatment. Emerging evidence suggests that the composition of gut bacteria may influence how well immunotherapy works. Some clinical trials are investigating whether modifying the microbiome through diet, probiotics, or fecal transplantation can improve responses to checkpoint inhibitors. This represents an exciting new frontier where patient lifestyle factors may directly impact treatment effectiveness.^[17]

For specific melanoma subtypes that tend to be more resistant to standard treatments, such as uveal (eye) melanoma and mucosal melanoma, dedicated research efforts are seeking better options. These rare forms often have different genetic characteristics than cutaneous melanoma and may require distinct treatment approaches. Clinical trials specifically for these subtypes are essential for progress.^[11]

Clinical trials are conducted in phases that serve different purposes. Phase I trials primarily assess safety and determine appropriate dosing of new treatments in small numbers of patients. Phase II trials examine whether the treatment shows signs of effectiveness against the cancer in a larger group. Phase III trials compare the new treatment directly against current standard therapy in large, randomized studies to definitively determine if it is better. Participation in any phase can be valuable, and eligibility criteria vary depending on prior treatments, overall health, and specific characteristics of the cancer.^[1]

Clinical trials for metastatic melanoma are being conducted worldwide, including in the United States, Europe, and many other countries. Information about available trials can be found through cancer centers, online databases maintained by organizations like the National Cancer Institute, and patient advocacy groups. Discussing clinical trial options with your oncology team is an important part of treatment planning.^[6]

Most common treatment methods

• Immunotherapy
  • PD-1 checkpoint inhibitors (nivolumab, pembrolizumab) given by intravenous infusion to activate the immune system
  • Combination checkpoint blockade with ipilimumab plus nivolumab for more aggressive immune activation
  • Nivolumab plus relatlimab targeting both PD-1 and LAG-3 checkpoints
  • High-dose interleukin-2 for selected patients requiring hospitalization
  • Localized immunotherapy with intralesional aldesleukin, topical imiquimod, or DPCP cream for accessible skin lesions
  • Tumor-infiltrating lymphocyte (TIL) therapy with lifileucel using a patient’s own engineered immune cells
• Targeted Therapy
  • BRAF/MEK inhibitor combinations for tumors with BRAF V600 mutations taken as daily oral pills
  • Dabrafenib combined with trametinib to block cancer cell growth signals
  • Vemurafenib combined with cobimetinib providing rapid tumor shrinkage
  • Encorafenib combined with binimetinib offering convenient dosing
  • Imatinib for rare tumors with C-KIT mutations
• Chemotherapy
  • Dacarbazine as a single agent approved since 1975
  • Combination chemotherapy regimens studied but not superior in extending survival
• Surgery
  • Removal of isolated metastases in skin, lymph nodes, or single organs when feasible
  • Brain surgery or gamma knife radiation for symptomatic brain metastases
• Radiation Therapy
  • Palliative treatment for painful bone metastases
  • Brain radiation for multiple brain metastases
  • Treatment of tumors causing symptoms by pressing on nerves or organs

Living with Metastatic Melanoma

A diagnosis of metastatic melanoma affects every aspect of life, and caring for your physical and emotional wellbeing is just as important as medical treatment. Many patients find that while they cannot control the cancer itself, they can take active steps to maintain the best possible quality of life during treatment and beyond.^[14]

Nutrition plays a supporting role in managing cancer and its treatment. While no specific diet can cure melanoma, eating a balanced diet helps maintain strength, supports the immune system, and can improve how you feel during treatment. Focus on getting adequate protein from sources like lean meat, fish, beans, and nuts to help prevent muscle loss and support healing. Choose whole grains and fiber-rich foods to maintain energy and prevent constipation, a common side effect of some medications. Colorful fruits and vegetables provide vitamins, minerals, and antioxidants. Staying well-hydrated is essential, especially if you experience diarrhea or other side effects. A dietitian experienced with cancer patients can provide personalized guidance.^[15]

Physical activity, even when you do not feel like exercising, can actually boost energy levels and combat the fatigue that often accompanies cancer and its treatment. Regular movement helps maintain muscle strength, improves mood, and reduces anxiety. The type and amount of exercise should be tailored to how you feel each day and your overall health status. Before starting any exercise program, discuss appropriate activities with your healthcare team. On difficult days, even gentle stretching or short walks can be beneficial.^[15]

Managing fatigue requires accepting that you have limited energy and making conscious choices about how to spend it. Prioritize activities that matter most to you, and do not hesitate to ask for help or decline invitations when needed. Saying no is an act of self-care, not selfishness. Keep a journal to identify patterns in your energy levels, which can help you plan activities for times when you typically feel best. If you find you cannot fall asleep within 15 minutes of going to bed, get up and do something calming rather than lying awake feeling frustrated.^[15]

Emotional support is vital throughout the melanoma journey. The stress, anxiety, and range of emotions that come with a metastatic cancer diagnosis are completely normal. Finding people you can talk to openly about your fears and feelings provides comfort and reduces isolation. Support can come from family and friends, professional counselors or therapists, or support groups where you connect with others facing similar challenges. Both in-person and online support groups exist specifically for melanoma patients, offering a space to share experiences, ask questions, and give and receive encouragement.^[2][14]

Some people find great comfort in spiritual practices or talking with religious leaders. Exploring what gives your life meaning and purpose can provide strength during difficult times. Additionally, focusing on activities you love and finding moments of joy, whether through hobbies, time with loved ones, nature, or creative pursuits, helps maintain your identity beyond the cancer diagnosis.^[14]

Managing treatment side effects proactively improves quality of life. Communicate openly with your healthcare team about any symptoms you experience, as many can be effectively treated. Pain management options range from medications to complementary approaches like acupuncture. If chemotherapy or radiation causes hair loss, some patients find it helpful to cut their hair short or shave their head before significant loss occurs, giving them a sense of control. Wigs, scarves, and hats are available, and some patients embrace their bald appearance. For swelling in arms or legs, compression garments may provide relief.^[15]

Regular follow-up care is essential for monitoring your response to treatment and catching any problems early. The frequency and type of monitoring depend on your treatment and individual situation. This typically includes physical examinations, blood tests including LDH levels, and imaging scans such as CT or PET scans. Some new treatments can cause late side effects months or even years after completion, so ongoing surveillance remains important even when treatment ends.^[16]

Financial concerns often arise during cancer treatment, as medical expenses can be substantial even with insurance. Social workers, patient navigators, or financial counselors at cancer centers can help identify available resources. Pharmaceutical companies often have patient assistance programs that help cover medication costs for those who qualify. Nonprofit organizations may offer grants for specific expenses like travel to treatment centers or heating costs. Do not hesitate to ask for help—these resources exist specifically to support patients facing cancer.^[5]

Planning ahead for medical decisions, including discussing your wishes with family and your healthcare team, provides peace of mind and ensures your preferences are known and respected. This includes considering advance directives and healthcare proxies, though these discussions do not mean giving up hope—they simply ensure you maintain control over your care in all circumstances.^[13]